Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
Douros J and Suffness M |
New natural products of interest under development at the National Cancer Institute. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:86390
|
Lu D et al. |
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:24939213
|
Wada R et al. |
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:25186956
|
Bender BC et al. |
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22886072
|
Carter SK |
New drugs under clinical evaluation in the United States. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:155503
|
Blum RH et al. |
A therapeutic trial of maytansine. |
1978 |
Cancer Clin Trials |
pmid:757139
|
|
T-DM1 aids patients with advanced breast cancer. |
2013 |
Cancer Discov |
pmid:24327714
|
|
T-DM1 Combo Graduates from I-SPY 2. |
2016 |
Cancer Discov |
pmid:27095360
|